Dartmouth + Innovation + Cancer

Many discoveries now revolutionizing the prevention and treatment of cancer can be traced back to Dartmouth—including immunotherapies for solid tumors, the integration of palliative care with cancer care, and the identification of cancer risks from environmental toxins and behaviors.
Source: News at Dartmouth Medical School - Category: Hospital Management Authors: Tags: Donor Impact Insider News Research campaign cancer Home-feature Interaction Norris Cotton Cancer Center Source Type: news

Related Links:

Authors: Jiang DM, Fyles A, Nguyen LT, Neel BG, Sacher A, Rottapel R, Wang BX, Ohashi PS, Sridhar SS Abstract Immunotherapy has shown modest activity in metastatic breast cancer (MBC). In this phase I dose escalation study, we assessed safety of tremelimumab, a humanized anti-CTLA4 monoclonal antibody, at starting dose 3 mg/kg, on the third day of palliative radiotherapy (2000cGy in 5 daily fractions) in patients with MBC. Primary objective was to determine the maximum tolerated dose (MTD) of tremelimumab combined with RT. Secondary objective was to assess response. Among 6 patients enrolled between July 2010 and O...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Radiotherapy plays an important role in the management of cancer patients. Radiotherapy is used in more than 50 % of patients during the course of their disease in a curative or palliative setting. In the past decades it became apparent that the abscopal effect induced by radiotherapy might be dependent on the activation on immune system and that the induction of immunogenic cancer cell death and production of danger-associated molecular patterns from dying cells play a major role in the radiotherapy-mediated anti-tumor efficacy. Therefore, the combination of radiotherapy and immunotherapy is of a particular interest that ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In the general population of metastatic colorectal cancer, microsatellite instability, andBRAF‐mutated tumors are more common than previously assumed. Unselected patients with microsatellite instability tumors are very different from patients included in the recent third line immunotherapy trials as most of them areBRAF‐mutated (non‐Lynch), they are older and receive less frequently palliative chemotherapy with limited effects. AbstractBackgroundImmunotherapy for patients with microsatellite ‐instable (MSI‐H) tumors orBRAF‐inhibitors combination treatment forBRAF ‐mutated (mutBRAF) tumors in metastatic colore...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Purpose of review Elderly head and neck cancer (HNC) patients are very rarely enrolled in clinical trials, and even more so in dedicated trials in curative or palliative setting. As a result, no standards of treatment exist for this population and thus, adaptation of standard treatments is commonly used. Recent findings The choice between a monotherapy and a platinum–cetuximab combination is based on the performance status, which is not suitable and/or sufficient to evaluate the patient ability to receive a systemic treatment combined or not with radiotherapy. The evaluation of functional age using geriatric ass...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: HEAD AND NECK: Edited by Joël Guigay Source Type: research
CONCLUSION: Our study strongly affirms the efficacy of an interdisciplinary approach including surgical and innovative medical strategies based on immunotherapy in patients with advanced chemo-resistant synchronous cervical and lung cancer. The present findings support the use of NGS to drive a targeted rational treatment especially in heavily pre-treated patients. PMID: 31007844 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Veterinary oncology has evolved rapidly over the past 30  years, with combinations of surgery, chemotherapy, immunotherapy, and radiation therapy now representing standard practice for managing pets with cancer. Recently, additional effort has been directed toward optimizing palliative strategies for mitigating clinical signs associated with advanced-sta ge disease, thereby reducing patient morbidity as pet owners navigate end-of-life decision making. This is a multi-dimensional, individualized process, which demands attention to the primary neoplastic condition, concurrent diseases, and emotional needs of the family....
Source: Veterinary Clinics of North America: Small Animal Practice - Category: Veterinary Research Authors: Source Type: research
BACKGROUND: Novel targeted treatments and immunotherapies have substantially changed therapeutic options for advanced and metastatic renal cell carcinomas (RCCs). However, accurate diagnostic tests for the identification of high-risk patients are urgently needed. Here, we analyzed SHOX2 mRNA expression in RCC tissues and SHOX2 gene body methylation quantitatively in circulating cell-free DNA (ccfDNA) and RCC tissues with regard to risk stratification. METHODS: The clinical performance of SHOX2 methylation was tested retrospectively and prospectively in a training and testing cohort of RCC tissue samples (n = 760 in total)...
Source: Clinical Chemistry - Category: Chemistry Authors: Tags: Molecular Diagnostics and Genetics Cancer Diagnostics Source Type: research
Immune checkpoint inhibitors (ICIs) are increasingly used to treat a variety of cancers, but comparatively little is known about patient-reported outcomes (PROs) and health-related quality of life (HRQoL) among patients receiving these novel therapies.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Source Type: research
Pulmonary pleomorphic carcinoma (PPC) is resistant to anticancer drug treatment, outcomes are poor, and no standard therapy has been established. High PD ‐L1 expression has been found in PPCs, suggesting the possible efficacy of an immune checkpoint inhibitor (ICI) in cancer immunotherapy; however, this approach requires further investigation through case accumulation. Herein, we report a case of rapid recurrence and progression of PPC early after surgery in a 70‐year‐old male ex‐smoker. Surgery was performed for lung cancer of the right lower lobe, and a pathological examination indicated primary PPC with high PD...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
AbstractFormenti et al. have recently reported the clinical outcomes and translational readouts of a trial of the anti-CTLA-4 inhibitor, ipilimumab, in combination with palliative radiotherapy in 39 patients with non-small cell lung cancer. A radiological response was seen in 18% of patients and 31% of patients experienced disease control. These clinical outcomes appear to be superior to historical studies using ipilimumab alone and suggest that radiation may have triggered systemic, so-called abscopal, immune responses in some patients. Induction of interferon-beta (IFN- β) and maximal expansion and contraction of di...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Environmental Health | Hospital Management | Immunotherapy | Palliative | Palliative Care